CytomX Therapeutics EPS - Earnings per Share 2014-2022 | CTMX

CytomX Therapeutics eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
CytomX Therapeutics Annual EPS
2021 $-1.30
2020 $-0.71
2019 $-2.26
2018 $-2.03
2017 $-1.16
2016 $-1.63
2015 $-4.90
2014 $-35.25
2013 $-24.46
CytomX Therapeutics Quarterly EPS
2022-06-30 $-0.37
2022-03-31 $-0.37
2021-12-31 $-0.39
2021-09-30 $-0.35
2021-06-30 $-0.30
2021-03-31 $-0.26
2020-12-31 $-0.31
2020-09-30 $-0.32
2020-06-30 $-0.34
2020-03-31 $0.26
2019-12-31 $-0.79
2019-09-30 $-0.52
2019-06-30 $-0.64
2019-03-31 $-0.31
2018-12-31 $-0.75
2018-09-30 $-0.53
2018-06-30 $-0.35
2018-03-31 $-0.40
2017-12-31 $0.04
2017-09-30 $-0.28
2017-06-30 $-0.69
2017-03-31 $-0.23
2016-12-31 $-0.40
2016-09-30 $-0.40
2016-06-30 $-0.39
2016-03-31 $-0.44
2015-12-31 $24.59
2015-09-30 $-14.26
2015-06-30 $-7.56
2015-03-31 $-7.67
2014-12-31 $0.00
2014-09-30 $-4.86
2013-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.110B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Zymeworks (ZYME) Canada $0.430B 0.00
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00